← Back to Screener
Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM)
Price$3.12
Favorite Metrics
Price vs S&P 500 (26W)-90.32%
Price vs S&P 500 (4W)29.74%
Market Capitalization$25.24M
All Metrics
Book Value / Share (Quarterly)$1.78
Cash Flow / Share (Quarterly)$-2.12
Price vs S&P 500 (YTD)-62.90%
Net Profit Margin (TTM)-9078.87%
EPS (TTM)$-8.72
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-8.72
EPS (Annual)$-7.97
ROI (Annual)-76.01%
Gross Margin (Annual)-641.58%
Cash / Share (Quarterly)$1.18
ROA (Last FY)-61.46%
Revenue Growth TTM (YoY)236.06%
EBITD / Share (TTM)$-4.20
ROE (5Y Avg)-75.83%
Operating Margin (TTM)-5052.26%
Cash Flow / Share (Annual)$-48.45
P/B Ratio2.66x
P/B Ratio (Quarterly)3.93x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-1.13x
ROA (TTM)-188.70%
EPS Incl Extra (Annual)$-7.97
Current Ratio (Annual)2.28x
Quick Ratio (Quarterly)1.06x
3-Month Avg Trading Volume0.01M
52-Week Price Return-18.89%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.62
P/S Ratio (Annual)94.42x
Asset Turnover (Annual)0.00x
52-Week High$52.00
EPS Excl Extra (Annual)$-7.97
26-Week Price Return-81.57%
Quick Ratio (Annual)2.22x
13-Week Price Return-56.70%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)1.07x
Enterprise Value$18.4
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-19353.53%
Cash / Share (Annual)$28.71
3-Month Return Std Dev180.64%
Net Income / Employee (TTM)$-3
ROE (Last FY)-77.29%
Net Interest Coverage (Annual)-1.13x
EPS Basic Excl Extra (Annual)$-7.97
Receivables Turnover (TTM)0.20x
Total Debt / Equity (Quarterly)0.27x
EPS Incl Extra (TTM)$-8.72
ROI (TTM)-316.78%
P/S Ratio (TTM)110.99x
Revenue / Share (Annual)$1.80
Price vs S&P 500 (52W)-30.71%
Year-to-Date Return-58.76%
5-Day Price Return-6.88%
EPS Normalized (Annual)$-7.97
ROA (5Y Avg)-64.82%
Net Profit Margin (Annual)-19353.53%
Month-to-Date Return-34.89%
EBITD / Share (Annual)$-4.19
Operating Margin (Annual)-13644.50%
ROI (5Y Avg)-74.32%
EPS Basic Excl Extra (TTM)$-8.72
P/TBV (Quarterly)11.29x
Inventory Turnover (TTM)4.70x
Pretax Margin (TTM)-9078.87%
Price vs S&P 500 (13W)-59.57%
Beta5.27x
Revenue / Share (TTM)$0.02
ROE (TTM)-417.59%
52-Week Low$2.85
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares | 110.99x | 236.06% | — | — | $3.12 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Quantum BioPharma is a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Its lead asset, Lucid-MS, is a patented therapeutic in preclinical development designed to prevent and reverse myelin degradation in multiple sclerosis. The company also maintains a portfolio of property-backed loans through a wholly owned subsidiary.